Institute of Pharmacology, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China.
Institute of Pharmacology, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China; Section of Endocrinology, School of Medicine, Yale University, New Haven 06520, USA.
Biochem Pharmacol. 2022 Mar;197:114817. doi: 10.1016/j.bcp.2021.114817. Epub 2021 Oct 27.
Glucagon-like peptide-1 (GLP-1) receptor-based therapies have been developed and extensively applied in clinical practice. GLP-1 plays an important role in improving glycemic homeostasis by stimulating insulin biosynthesis and secretion, suppressing glucagon activity, delaying gastric emptying, and reducing appetite and food ingestion. Furthermore, GLP-1 has positive effects on β-cell function by promoting β-cell proliferation and neogenesis while simultaneously reducing apoptosis. Here, we summarize possible mechanisms of action of GLP-1 upon pancreatic islets as well as describe phytochemicals that modulate pancreatic islet β cell function through glucagon-like peptide-1-related mechanisms. Together, this information provides potential lead compound candidates against diabetes that function as GLP-1 receptor-based pharmacotherapy.
胰高血糖素样肽-1(GLP-1)受体为基础的治疗方法已经开发并广泛应用于临床实践。GLP-1 通过刺激胰岛素的生物合成和分泌、抑制胰高血糖素的活性、延缓胃排空以及减少食欲和食物摄入,在改善血糖稳态方面发挥着重要作用。此外,GLP-1 通过促进β细胞的增殖和新生,同时减少细胞凋亡,对β细胞功能具有积极作用。在这里,我们总结了 GLP-1 对胰岛的可能作用机制,并描述了通过 GLP-1 相关机制调节胰岛β细胞功能的植物化学物质。这些信息为基于 GLP-1 受体的药物治疗提供了对抗糖尿病的潜在先导化合物候选物。